AzTrials
AzTrials

HIV SeropositivityEarly CCLADNCT04736316

Early Community Client-LED ART Delivery in Nakivale Refugee Settlement

A study testing Early CCLAD in people with HIV Seropositivity, run by University of Washington at 1 site in Uganda.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

To pilot early community client-led ART (anti-retroviral therapy) delivery (CCLAD) in Nakivale Refugee Settlement in Uganda and assess the feasibility and acceptability of this intervention in this setting. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
HIV Seropositivity
What is being tested?
Early CCLAD
Could I receive a placebo?
No, everyone receives an active treatment
How many people
92 participants
Where
1 siteUganda
Study dates
29 Jun 2020to 31 Mar 2022
Phase
Interventional
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Adults ≥ 18 years of age who present to the Nakivale Health Center and agree/consent to test for HIV.

Who cannot join

  • Unable to understand one of the study languages (English, Kinyarwanda, Kiswahili, Runyankore).
  • Subjects who do not test positive for HIV at health center will not be eligible to participate in the early community-based client-led antiretroviral therapy delivery intervention

Trial locations and contacts

1 site in 1 country.

Uganda1 site
  • Nakivale Refugee Settlement

    Isingiro

Other trials in Uganda

About this study

Official title: Early Community Client-Led ART Delivery (CCLAD) to Optimize HIV Care Engagement in Nakivale Refugee Settlement

To pilot early community client-led ART (anti-retroviral therapy) delivery (CCLAD) in Nakivale Refugee Settlement in Uganda and assess the feasibility and acceptability of this intervention in this setting.

Read the detailed description

Adults accessing routine HIV testing in Nakivale Refugee Settlement will be invited to participate. The study population will include adult refugees and Ugandan nationals of all genders older than 18 years of age. Pregnant women will be invited but Maternal Health Clinic will determine if they participate. Those that test positive for HIV will be invited to participate in the Early Community Client-Led ART Delivery group intervention.

Individuals will be offered research participation which will include an intake survey, an HIV test, and the option to participate in early community client-led ART delivery (early CCLAD) groups if diagnosed with HIV. Those interested in participating will have a consent form read aloud to them by a Research Assistant before being tested for HIV. Consent forms will be available in 4 languages: Runyankore, Kinyarwanda, Kiswahili and English, and will be read by multi-lingual Research Assistants. These individuals will be told at the outset that they can alternatively access free HIV testing at the outpatient department clinic if they prefer to not participate in any aspect of the research. After consent but prior to HIV testing, the investigators will conduct a baseline survey. This will include collection of contact information, demographic information, physical assessment, migration patterns, HIV testing history, perceived stigma, screening for mental disorders, and assessment of social support. Like the consent process, the survey will be available in 4 languages: Runyankore, Kinyarwanda, Kiswahili or English, and will be read aloud to participants with responses entered directly into a passcode-protected electronic tablet.

The first meeting of each Early CCLAD group will include an HIV clinic clinician. The first meeting is the one time in the intervention where participants will be compensated for their transportation to the clinic or to the meeting site (20,000 USH will be provided for each participant who attends this meeting). The HIV clinician, who will have been trained in the Early CCLAD group intervention, will help individuals in the group to understand their roles and responsibilities. The group will work together to plan future meeting dates and locations. The participants will decide if they would like to support the person responsible for picking up the ART each month (e.g. money, transportation, childcare, food). The participants will specify which dates they will be responsible to attend HIV clinic and pick up ART for the group. They will discern if they would like to identify a connecting activity to be integrated into their group (e.g. exercise, faith, livelihood, craft). The participant group will select a Team Leader to coordinate communication between the group and the healthcare facility. Finally, an important part of this first meeting is that the HIV clinician will conduct a standard comprehensive clinical exam and will refer each person/participant for any necessary laboratory testing.

Monthly "Early CCLAD" meetings: The "Early CCLAD" intervention will require monthly group meetings. This is intentionally more frequent than is suggested in the Ugandan Ministry of Health guidelines (which recommends visits every 3 months) as this intervention will occur at the time of diagnosis rather than when a person is deemed "stable" in care. Before the designated individual goes to clinic in any given month, they will be responsible for connecting with each group member to ask about how they are feeling and to see if they have any questions to ask of the HIV clinic staff. That individual will then attend HIV clinic and communicate about the status of each group member. They will collect information from the clinic and pre-packed ART for each group member. The "Early CCLAD" group will then meet at their predetermined location so that the individual who attended clinic can share information from the clinic and can distribute the ART to each person in the group. If a participant misses a CCLAD group, they can present to the HIV clinic to pick up their ART refill if a member of the group cannot arrange delivery or pickup.

Additional clinic attendance: All participants assigned to an "Early CCLAD" group will be expected to attend HIV clinic in person twice yearly for a clinical evaluation and a viral load check. The HIV clinician will work with the team to decide if they prefer their twice annual HIV clinic visits on the same day but individually, on the same day as a group, or individually on different schedules from others in the group. Additionally, individuals will attend clinic in person when they do not feel well, when they have any questions they prefer to ask the clinicians directly, when additional laboratory testing is required, and when requested by HIV clinic staff to optimize their medical care. In cases where the participants are deemed clinically unstable and are in need of regular clinical follow up (e.g. develops an opportunistic infection, develops other co-morbidity, has a viral load > 1,000 copies/mL), clients will be asked to attend the clinic monthly with the rotating group member collecting group ART refill or to step in as the group member responsible for attending clinic that month. Individuals "Up referred" by HIV clinic staff to monthly HIV clinic visits should still participate in the "Early CCLAD" groups to receive psychosocial support and other benefits of community group care.

Option to stop the "Early CCLAD" group at any time: Participants can opt to stop Early CCLAD participation at any time. If willing, they will be asked to participate in a brief exit interview so the investigators can better understand what aspects of the intervention were acceptable or not acceptable to them.

"Early CCLAD" groups and HIV clinic connectedness: To ensure the Early CCLAD intervention participants remain well integrated into HIV clinic, the research staff will meet regularly with the HIV clinic staff to update them on the intervention and to discuss specific problems and specific individuals needing specialized care. Additionally, efforts will be made so that participant HIV clinic files and pre-packed medications are ready for the visit of the individual Early CCLAD group member each month. Finally, participants will be reminded frequently that they are expected and welcome to attend clinic when they do not feel well or when they have any questions or needs that are not being met through group care.

Follow-up data collection: Early CCLAD group participants will be given components of the intake survey (i.e. to assess mental health screening, perceived stigma, and social support) again 6-months after they began participation in the intervention. Some of this may occur in an interview setting which is recorded and then later transcribed. Additionally, data will be collected to assess retention in group care, ART medication pick-up, and HIV clinic outcomes.

Being tested
Early CCLAD
Medical subject headings
HIV Seropositivity

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Early CCLADBehavioural

    Community-based client led antiretroviral therapy delivery groups.

Study groups in NCT04736316
Study groupRoleWhat they receive
Early CCLADExperimentalEarly community client-led ART delivery groups
Receives: Behavioral: Early CCLAD

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Number of Participants in HIV Care (Linkage) Among the Early CCLAD Participants

    Attendance in one Early CCLAD group meeting (yes/no)

    Measured: Within 90 days of study initiation excluding the day of diagnosis

  2. Number of Early CCLAD Group Visits Attended (Retention) Among Early CCLAD Participants

    Attendance in monthly Early CCLAD group meetings (yes/no). With an intention to treat, description of how many monthly group meetings were attended in the first 6 months of the intervention including Early CCLAD community visits, but not including HIV clinic visits

    Measured: 6 months

  3. ART Initiation

    Number of participants who picked up anti-retroviral therapy (ART) at least once over the 6 month period as documented in the written HIV clinic record

    Measured: 6 months

  4. Clinical Outcomes: Number of Participants With Viral Suppression

    Viral suppression defined by <1000 copies/mL or CD4 count >250 cells/mm3 as documented in the HIV clinic records

    Measured: 6 month period

  5. Total Number of Clinic Visits Per Participant (Incl. CCLAD Visits)

    All clinic and CCLAD visits per participant

    Measured: 6 months

  6. Survey Score Related to Psychosocial Factors: Perceived Health

    Question: "In general, would you say your health is excellent, very good, good, fair or poor?" Answer options: "Excellent, very good, good, fair, poor, do not know, no answer" This is among participants who completed both baseline and follow-up surveys only.

    Measured: baseline survey and 6 month follow-up survey

  7. Survey Score Related Factors: Screened Positive for Depression

    Depression measured via Patient health questionnaire depression assessment (PHQ-9); 9 questions with 0-3 score for each answer. Interpretation of score: 0-4= minimal or no depression; 5-9= mild depression; 10-14=moderate depression. For this study, we considered a positive screen for depression as a PHQ-9 score of >=10.

    This analysis includes only those who participated in baseline and 6 month surveys.

    Measured: baseline and 6 month surveys

  8. Survey Score Related Factors: Screened Positive for Anxiety

    Anxiety measured via Generalized anxiety disorder (GAD-7) tool; 7 questions with 0-3 score for each answer; Interpretation of total score: 0-4=minimal anxiety; 5-9= mild anxiety; 10-14=moderate anxiety; 15-21=severe anxiety. For this study, those with a score of >= 10 were considered to have screened in for anxiety.

    This analysis includes only those who participated in baseline and 6 month surveys.

    Measured: Baseline and 6 months

  9. Survey Score Related Factors: Screening Positive for PTSD

    PTSD measured via Post-traumatic stress disorder (PCL-6) scale; 6 questions with 1-5 score for each question; Interpretation of Total score: greater than or equal to 14 is a positive screen.

    This analysis includes only those who participated in baseline and 6 month surveys.

    Measured: baseline and 6 month surveys

  10. Survey Score Related Factors: Screening Positive for Low of Social Support

    Social Support measured via Social support (BS6) scale; 6 questions with scores 1-4 for each answer; Interpretation of total score: 6-11= low (a positive screen for lack of social support), 12-17=moderate (at least occasional support); 18-23= high; 24=very high (maximum, always supported). For this study we considered <= 11 as a positive screen for low of social support.

    This analysis includes only those who participated in baseline and 6 month surveys.

    Measured: baseline and 6 month surveys

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted3 Feb 2021
  2. Study start29 Jun 2020
  3. Primary completion31 Mar 2022
  4. Study completion31 Mar 2022

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Health services research
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
92 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04736316
Sponsor's protocol ID
STUDY00008718
Other IDs
K23MH108440
Acronym
Early CCLAD
Status last verified
Jun 2023
First submitted
27 Jul 2020
Last updated
11 Jul 2023
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No: Pilot research findings will be shared in a peer-reviewed journal. Additional research data sharing requests will be considered by the PI.

Publications

  • Parrish C, Lewis S, Faustin Z, Klabbers R, Nshimiyimana V, Eilers B, Iraguha P, Muwonge T, O'Laughlin KN. Community client-led anti-retroviral therapy delivery for people newly diagnosed with HIV: a pilot study in Nakivale Refugee Settlement in Uganda. AIDS Care. 2025 Feb;37(2):300-309. doi: 10.1080/09540121.2024.2436559. Epub 2024 Dec 12.

    PubMed 39666852

Questions about this trial

What is this clinical trial studying?

A study testing Early CCLAD in people with HIV Seropositivity, run by University of Washington at 1 site in Uganda.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 11 Jul 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Uganda. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Yes. Results are posted in the registry (first posted 11 Jul 2023). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Number of Participants in HIV Care (Linkage) Among the Early CCLAD Participants (time frame: Within 90 days of study initiation excluding the day of diagnosis). The study lists 10 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04736316, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 Jul 2023.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in